Quarterly report [Sections 13 or 15(d)]

Consolidated Balance Sheets

v3.26.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Current Assets    
Cash and cash equivalents $ 216,366 $ 358,975
Marketable securities — related party 10,629 38,531
Unbilled receivable 32,667
Total Current Assets 259,662 397,506
Total Assets 259,662 397,506
Current Liabilities    
Accounts payable and accrued expenses 420,636 359,380
Convertible note payable 25,000 25,000
Derivative liability 1,238,750 1,944,806
Total Current Liabilities 3,129,045 3,773,845
Total Liabilities 3,129,045 3,773,845
Commitments and Contingencies (Note 8)
Stockholders’ Deficit    
Preferred stock, $0.0001 par value, 50,000,000 shares authorized; none issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value: 500,000,000 shares authorized; 46,852,319 and 46,852,319 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 4,685 4,685
Additional paid-in capital 34,599,775 34,270,622
Accumulated deficit (37,473,843) (37,651,646)
Total Stockholders’ Deficit (2,869,383) (3,376,339)
Total Liabilities and Stockholders’ Deficit 259,662 397,506
Related Party [Member]    
Current Liabilities    
Accounts payable — related party 926,659 926,659
Short-term advances — related party 18,000 18,000
Notes payable — related party $ 500,000 $ 500,000